SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bandari Jathin

(Last)

(First)

(Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/10/2022

3. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,500⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	06/30/2030	Common Stock	14,500	$28.2	D
Stock Option (right to buy)	⁽³⁾	08/31/2030	Common Stock	2,500	$20.51	D
Stock Option (right to buy)	⁽⁴⁾	01/18/2031	Common Stock	13,877	$19.82	D
Stock Option (right to buy)	⁽⁴⁾	01/18/2031	Common Stock	11,123	$19.82	D
Stock Option (right to buy)	⁽⁵⁾	09/30/2031	Common Stock	523	$6.95	D
Stock Option (right to buy)	⁽⁵⁾	09/30/2031	Common Stock	1,977	$6.95	D
Stock Option (right to buy)	⁽⁶⁾	10/31/2031	Common Stock	1,355	$7.02	D
Stock Option (right to buy)	⁽⁶⁾	10/31/2031	Common Stock	5,145	$7.02	D

Explanation of Responses:

1. The shares reported are issued pursuant to a restricted stock unit award (RSU), of which represents a contingent right to receive one share of Issuer's common stock. The RSU vest in equal one-fourth installments on the first, second, third and fourth anniversaries of July 1, 2020.

2. 25% of the shares vest on the one year anniversary of July 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

3. 25% of the shares vest on the one year anniversary of September 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

4. 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

5. 25% of the shares vest on the one year anniversary of October 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

6. 25% of the shares vest on the one year anniversary of November 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

	Mary Grendell, Attorney-in-Fact	01/10/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.